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Abstract
Background: The loss of CD20 protein expression after a rituximab-containing regimen is one of the resistance
mechanisms in non-Hodgkin's lymphoma. Recently, it was reported that 5-azacitidine administration upregulates
the expression of CD20 in CD20-negative B-cell acute lymphoblastic leukemia. Here we report a similar
upregulation in a patient with follicular lymphoma who was treated with 5-azacitidine against secondary
myelodysplastic syndrome.
Case presentation: A 69-year-old Japanese woman with follicular lymphoma with treatment-related myelodysplastic
syndrome was negative for the CD20 antibody at the time of her relapse. After treatment of 5-azacytidine for her
myelodysplastic syndrome, CD20 expression was upregulated in the follicular lymphoma cells in her peripheral blood.
We also observed follicular lymphoma cell stimulation in her peripheral blood due to 5-azacytidine.
Conclusions: Although partial, CD20 expression was upregulated after treatment with 5-azacitidine. However, CD20
expression was not re-upregulated after a second administration of 5-azacitidine and we also observed the risk of
lymphoma cell stimulation due to 5-azacitidine.
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Background
Rituximab is a standard drug for the treatment of CD20-
positive B-cell non-Hodgkin's lymphoma (NHL). The
loss of CD20 protein expression after a rituximab-
containing regimen is one of the resistance mechanisms
in NHL [1, 2]. Recently, it was reported that 5-azacitidine
(5-AZA) administration upregulates the expression of
CD20 in CD20-negative B-cell acute lymphoblastic
leukemia [3]. Here we report the case of a patient who
was treated with 5-AZA against secondary myelodysplas-
tic syndrome (MDS) that was caused by the treatment of
B-cell follicular lymphoma (FL). CD20 expression was
upregulated in CD20-negative FL cells after 5-AZA
treatment.
Case presentation
A 69-year-old Japanese woman developed grade 2 FL
and exhibited symptoms that included swelling in her
neck, pharyngeal tonsils, and axial and inguinal lymph
nodes with FL invasion of her bone marrow. The
lymphoma cells were also positive in her peripheral
blood, and her clinical stage was IVA. Her FL inter-
national prognostic index (FLIPI) was assessed to be
high risk based on her age, swollen lymph nodes,
clinical stage IV, and lactate dehydrogenase (LDH)
levels that were higher than the normal range. She
had no pertinent family and psychosocial history. She
was given six courses of R-THP-COP treatment
(rituximab 375 mg/m2 on day 1, pirarubicin 30 mg/
m2 on day 2, cyclophosphamide 500 mg/m2 on day 2,
vincristine 1 mg/m2 on day 2, and prednisolone
30 mg/m2 on days 2 to 6) and achieved complete
remission (CR). The disease recurred approximately
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9 months later, and she was treated with a combin-
ation of bendamustine (90 mg/m2 for 2 days) and
rituximab (375 mg/m2 for 1 day). She achieved partial
remission (PR) and the FL cells disappeared: FL cells –
CD10 and CD19 double-positive cells and IgH-BCL2 posi-
tive in polymerase chain reaction (PCR); however, in her
peripheral blood (IgH-BCL2 negative by PCR and CD20-
positive cell was negative in peripheral blood), FL recurred
and a therapy-related MDS simultaneously developed
16 months after the diagnosis. Her pancytopenia and
normal karyotype indicated a score of 2.5 points: blast cell
0.8 %; hemoglobin 11.1 g/dl; platelet count 6.7×109/L;
absolute neutrophil count 0.4×109/L. Her revised inter-
national prognostic score showed an intermediate low
risk. FL cell specimens were harvested from her peripheral
blood. The CD20 protein expression in the lymphoid cells
was analyzed by flow cytometry in which mouse anti-
CD20 antibody (B2E9; Beckman Coulter, Fullerton, CA,
USA) was used. The FL cells in her bone marrow and
peripheral blood were CD20-negative. The clinical
course of the first 5-AZA treatment is shown in Fig. 1.
She was treated with 75 mg/m2 of 5-AZA against
therapy-related MDS for 7 days. Of interest, 10.8 %
of the CD20-negative lymphoma cells had restored
CD20 expression after 5-AZA was administered
(Fig. 2). Circulating FL cells also increased after its
administration. We administered rituximab (375 mg/m2)
1 day after the last administration of 5-AZA to prevent
the progress of FL. After administration of rituximab, we
administered 375 mg/m2 of rituximab again and an 80 %
dosage of a GDP regimen that contained 1000 mg/m2 of
gemcitabine, 75 mg/m2 of cisplatin and dexamethasone 20
mg orally on days 1-4. She was treated with a second
course of 5-AZA against MDS, but CD20 expression
was not restored in the FL cells in her peripheral
blood (Fig. 2).
Discussion
The loss of CD20 expression is often observed after
rituximab treatment in CD20-positive NHL [1, 2]. In
the present case, the expression of CD20 protein
gradually lost negative after bendamustine and rituxi-
mab treatments. Although a loss of CD20 expression
is often associated with transformation in the FL to
diffuse large B-cell lymphoma (DLBCL) [1, 2], the
histology remained FL at the time of the loss of the
CD20-negative transformation. This suggests that the
phenomenon of CD20 expression does not necessarily
indicate a transformation from FL to DLBCL.
Our patient’s FL was complicated by therapy-related
MDS, and 5-AZA was administered for MDS. Following
the first cycle of 5-AZA treatment, a small proportion of
the CD20-negative cells exhibited CD20 expression. We
also observed the risk of lymphoma cell stimulation due
to 5-AZA. However, CD20 expression was not restored
in the FL cells in her peripheral blood after the second
course of 5-AZA. One possibility was that GDP-
rituximab might have eliminated the FL clone, which
restored the CD20 protein by 5-AZA. Another possibil-
ity was that the FL cells might have obtained a new
chromosomal abnormality.
Fig. 1 Clinical course of first 5-azacitidine treatment and changes of CD19 and CD10 double-positive lymphoma cells. 5AZA 5-azacitidine, FL follicular
lymphoma, WBC white blood cells
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Recent studies demonstrated that CD20 protein and its
messenger ribonucleic acid (mRNA) expression were
enhanced in a CD20-negative transformed cell line RRBL1
in a culture with 5-AZA in vitro [1, 4]. 5-AZA upregulated
CD20 due to the stimulation of transcription factors that
stimulate MS4A1 by the regulation of the CpG methylation
of gene promoters. This phenomenon restored the sensitiv-
ity of the FL cells to rituximab [1, 3, 4]. Our case further
proved these in vitro findings in vivo. However, the effects
of 5-AZA on CD20 induction were partial. In vitro studies
demonstrated that the maximal effect of 5-AZA for the ex-
pression of the CD20 protein was observed 3 days after 5-
AZA treatment [1, 4]. Therefore, a much earlier evaluation
of CD20 expression after 5-AZA and earlier administration
of rituximab following 5-AZA therapy may be required.
Conclusions
Although there was partial upregulation of CD20 expres-
sion after 5-AZA treatment, it was not observed after a
second administration of 5-AZA; we also observed
lymphoma cell stimulation due to 5-AZA. Further stud-
ies must address these issues.
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Fig. 2 Seven-day administration of 5-azacitidine followed by 1-day rituximab treatment. CD20 expression restored in CD20-negative lymphoma
cells but not in second course. 5AZA 5-azacitidine
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